Home / Health / Novo Nordisk Drug Shows Major Weight Loss
Novo Nordisk Drug Shows Major Weight Loss
24 Feb
Summary
- UBT251 achieved up to 19.7% weight loss in 24 weeks.
- The trial involved Chinese participants with overweight or obesity.
- The drug is a once-weekly injectable targeting GLP-1, GIP, and glucagon.
A promising new weight loss drug, UBT251, developed by Novo Nordisk and United Biotechnology, has demonstrated significant efficacy in a clinical trial. The triple agonist, which targets receptors for GLP-1, GIP, and glucagon, achieved a mean weight loss of up to 19.7% over a 24-week period.
The trial specifically focused on Chinese individuals diagnosed with overweight or obesity. Participants were administered once-weekly injectable doses of UBT251 at 2 mg, 4 mg, or 6 mg. In comparison, the placebo group experienced a mean weight loss of only 2.0% during the same timeframe.
These results suggest UBT251 could be a powerful new tool in managing obesity. The drug's mechanism of action and its effectiveness in this trial provide substantial hope for future obesity treatments.
